Irina V. Berezhnaya

Irina V. Berezhnaya

Auto-generated profile, based on publicly available information

Irina V. Berezhnaya

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
IOIsmail M. Osmanov
Ismail M. Osmanov
TTTatiana M. Tvorogova
Tatiana M. Tvorogova
IBIrina V. Berezhnaya
Irina V. Berezhnaya
AMAnastasia V. Makhaeva
Anastasia V. Makhaeva
МВМахаева Анастасия Владимировна
Махаева Анастасия Владимировна
Post-covid syndrome (PCS) is a symptom complex that occurs during and after COVID-19 lasting more than 12 weeks, which is not a possible disease. The clinical manifestations of PCS are many-sided, under their mask or manifestations or exacerbations of chronic organic activity, the trigger of which was the virus, are hidden. PCS is a diagnosis of exclusion. The main manifestations of PCS: autonomic dysregulation, cognitive and psycho-emotional disorders, disorders of the respiratory system, cardiovascular, digestive systems. Direct pathogenic factors, the main neurological manifestations are PCS of preservation of brain hypoperfusion, hypoxia and hypoxemia, resulting in energy deficiency of neuronal structures, violation of the probable, as well as virus-induced structural detection of neurons in the cortex and subcortical structures of the brain. The severity and duration of exposure appear to be increasingly dependent on the body's response to SARS-CoV-2. PCS has a different severity of severity in recovered patients and does not always depend on the severity of the acute period. Timely examination with differential diagnosis allows not only to make a diagnosis, but also to recommend therapy with a personalized approach to the correction of PCS.

6 June 2023 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
ODOlga V. Dedikova
Olga V. Dedikova
IZIrina Zakharova
Irina Zakharova
AKAnastasiya E. Kuchina
Anastasiya E. Kuchina
IBIrina V. Berezhnaya
Irina V. Berezhnaya
NSNarine G. Sugian
Narine G. Sugian
Many studies have been devoted to human microbiome. It has been shown that the microbiome has a significant effect on almost all the vital functions of the host organism. The article addresses the role of various factors in newborns' intestinal microbiota formation. The main emphasis was on the delivery method since the intestinal microbiota of children born via vaginal delivery differs from those born by cesarean section. The microbiota of the mother's intestine and vagina greatly influences the formation of the intestinal microbiome. The delivery method affects not only the formation of the intestinal microbiota but also, indirectly, the development of the newborn's immune system. Changes in the intestinal microbiota associated with surgical delivery probably affect the formation of a newborn infant's immune system. Lack of colonization by the mother's flora during delivery may contribute to a greater risk of infectious and non-communicable diseases. Correcting the microbiota of children born by cesarean section using probiotics (mono- or multistrain probiotics) is essential. When prescribing a probiotic, it is important to choose a well-studied strain shown to be safe, with a positive experience in newborns, and approved for use in children from birth.

8 June 2024 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
IBIrina V. Berezhnaya
Irina V. Berezhnaya
IKIrina S. Kuznetsova
Irina S. Kuznetsova
NDNatalia F. Dubovets
Natalia F. Dubovets
ДФДубовец Наталья Федоровна
Дубовец Наталья Федоровна
The incidence of acute respiratory infections has remained the same for decades. About 70–80 thousand cases per 100 thousand children are registered annually in the Russian Federation, which is 3.3 times higher than in adults. For the last reporting year, 2022, the incidence of acute respiratory viral infections (ARVI) was almost twice the long-term average. Influenza is a highly contagious severe respiratory infection, the incidence of which peaked in December 2022. At the beginning of the epidemic season, influenza A(H1N1) pdm09 viruses prevailed, and then they were joined by influenza B viruses with more severe disease than in previous years. Compared to 2021, the number of reported cases is 4 times higher, twice the long-term average. Most respiratory viral infections, having their specific features, involve the nasal mucosa and oropharynx and manifest with sore throat, rhinitis, cough, and fever. The study of the oral and pharyngeal microbiota by 16S rRNA gene sequencing showed that in patients with ARVI, there is a significant decrease in the α-diversity of bacteria and the loss of a healthy basic microbiota, in particular anaerobes and Prevotella spp. At the same time, eight respiratory pathogens were identified, including Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, lichen pigmentosa and Corynebacterium propinquum/pseudodiphtheriticum, which commonly cause bacterial complications, especially in children with frequent respiratory infections. The article addresses the treatment of ARVI and tonsillopharyngitis in children following clinical guidelines and the prospects of using topical agents for inflammation of the oropharynx in children.

24 November 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
IBI. V. Berezhnaya
I. V. Berezhnaya
AKA. Е. Kuchina
A. Е. Kuchina
ODO. V. Dedikova
O. V. Dedikova
The review is devoted to the analysis of data on the effects ofLactobacillus reuteriDSM 17938, confirmed in clinical trials. Thanks to their antimicrobial activity,L. reuteriis able to inhibit colonization by pathogenic microorganisms and restore the composition of compensatory intestinal microbiota. Another study showed a positive protective effect of intestinal microbiota when administeredL. reuterisimultaneously with antibiotics. In addition,L. reuterisupports the immune system of the human body. For example, some strains ofL. reuterimay reduce the production of pro-inflammatory cytokines while stimulating the development and proliferation of regulatory T-lymphocytes. AddingL. reuterito the diet may be attractive in terms of preventing the development of inflammatory bowel disease. The results of a recent meta-analysis confirmed the efficacy ofL. reuteriin the treatment of infantile colic. Further research is aimed at finding evidence of the efficacy ofL. reuteriuse in children who are artificially fed, with infant colic and in children born by caesarean section.

28 February 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
IBI. V. Berezhnaya
I. V. Berezhnaya
NSN. G. Sugyan
N. G. Sugyan
TTT. M. Tvorogova
T. M. Tvorogova
DKD. S. Kolushkin
D. S. Kolushkin
IRI. E. Rodionov
I. E. Rodionov
Introduction. The WHO recommends using acetaminophen (paracetamol) and ibuprofen in fever treatment in children and does not recommend their use in sequence to avoid overdose. However, in recent years, preparations containing both medicinal components have appeared, which allows fever to be relieved safely and the daily dosage of the medicines to be reduced.Objective. To obtain additional data on the efficacy and safety of antipyretic drug combination in comparison with mono drugs in children with the febrile syndrome in acute upper respiratory tract infectionsMaterials and methods. Single-center non-interventional (observational) comparative study was conducted in children from 3 to 12 years of age with acute respiratory infections accompanied by fever. Children were divided into 3 groups: the treatment group (83 children) received a combined antipyretic drug in the form of dispensable tablets (100 mg ibuprofen and 125 mg paracetamol); control group 1 (42 children) received paracetamol in the form of suspension; control group 2 (43 children) received ibuprofen in the form of suspension. The clinical efficacy and safety of antipyretic therapy and also the satisfaction of the patients’ parents, were evaluated in the dynamics.Results. The results showed similar efficacy and safety of all three medications, but the daily dose of medications with the combined dispersible tablets was lower, more so for paracetamol and somewhat less so for ibuprofen. In the combined dispersible tablets group, the proportion of patients with a temperature < 37.2 °C was statistically significantly higher 1 hour after administration than in the paracetamol and ibuprofen drug groups. Ibuprofen only compared with the study drug in terms of efficacy after 2 hours, while paracetamol was already effective after 3 hours.Conclusions. The study showed that the combined drug in the form of dispersible tablets (100 mg of ibuprofen and 125 mg of paracetamol) showed statistically significant efficacy parameters, is safe and well-tolerated by patients.

1 January 2021 in Russian Otorhinolaryngology
Verified
Journal Article
Open access
MEMoscow Russian Medical Academy Of Continuing Professional Education
Moscow Russian Medical Academy Of Continuing Professional Education
IZIrina Zakharova
Irina Zakharova
MHMoscow Bashlyaev Children’s City Clinical Hospital
Moscow Bashlyaev Children’s City Clinical Hospital
NGNatalia Geppe
Natalia Geppe
NSN. G. Sugyan
N. G. Sugyan
IBI. V. Berezhnaya
I. V. Berezhnaya
In accordance with modern clinical guidelines, systemic antibiotic therapy for infectious and inflammatory diseases of the throat is recommended only when beta-hemolytic group A streptococcus is detected. In other cases, it is advisable to use topical drugs of etiotropic, pathogenetic and symptomatic action. The combined preparation Grammidin® has a wide spectrum of etiotropic activity (antiviral, antibacterial and antifungal). Objective of the study: to assess the safety and efficacy of the use of Grammidin® for children (dosage form – metered spray) in the treatment of inflammatory diseases of the pharynx in preschool children. Materials and methods. An open comparative multicenter randomized study was carried out in two parallel groups with the participation of 160 patients aged 3–5 years with an infectious-inflammatory disease of the pharynx of nonstreptococcal etiology. The disease was established clinically by the presence of: a symptom of «sore throat» according to the Wong-Baker (WB) scale, as well as two or more local signs of acute inflammation of the oropharynx (hyperemia of the pharyngeal mucosa, edema of the pharyngeal mucosa, edema of the soft tissues of the posterior and lateral pharyngeal walls, an increase in lymphoid granules of the posterior pharyngeal wall and lateral columns, swelling of the uvula) according to pharyngoscopy. The randomized patients received Grammidin® for children or Hexoral® for 7 days according to the instructions for medical use. Safety was assessed by the incidence of adverse events (AEs) and by monitoring vital signs (body temperature, blood pressure, respiration and heart rate) with monitoring of blood and urine tests. Efficacy was assessed by the decrease in mean disease severity (modified TSS) at visit 2 from baseline – the primary endpoint. Changes were used as secondary endpoints: the severity of the disease (TSS scale), the severity of the sore throat symptom (WB scale), the severity of each of the catarrhal symptoms initially identified according to pharyngoscopy data, the proportion of patients with no sore throat (WB scale), the proportion of patients with the absence of all catarrhal phenomena (pharyngoscopy) at visits 2 and 3. Results. Primary efficacy endpoint: change in mean disease severity on the TSS scale at Visit 2 from baseline in Group 1 was –1,80 (95% CI –1,98 – –1.61) points and –1,31 (95 % CI –1,50 – –1,12) points - in group 2 (p = 0.003). Secondary performance endpoints. According to the analysis of variance in Group 1, there was a statistically significant predominance of the therapeutic effect throughout the treatment in relation to the severity of the disease on the Total Symptoms Score (TSS) scale (p = 0,006), the severity of sore throat on the WB scale (p = 0,006), as well as the severity of individual signsof the disease: «Hyperemia of the pharyngeal mucosa» (p = 0,036) and «edema of the pharynx» (p = 0,037). The rates of relief of symptoms: «the severity of lymphoid granules of the posterior pharyngeal wall and lateral columns» and «uvula edema» were similar in both groups. The proportion of children with no sore throat at visit 2 was statistically significantly different: 46 and 29% for Group 1 and Group 2, respectively (p = 0,022). Safety assessment. In the course of the study, 1 child was registered in each group who developed 1 AE of mild severity, had a doubtful connection with the study drugs, did not require their cancellation and additional therapy, and spontaneously ended without consequences by visit 3. Conclusions. The combined drug Grammidin® for children in the form of a metered spray was well tolerated by children aged 3–5 years and according to a number of main criteria of efficacy (total severity of symptoms of the disease, sore throat, hyperemia and swelling of the pharyngeal mucosa) showed a pronounced and statistically significant advantage in speed and severity effect over a monocomponent preparation containing hexetidine in the form of an aerosol.